UTL-5g

Drug Profile

UTL-5g

Alternative Names: UTL 5g

Latest Information Update: 15 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 21st Century Therapeutics
  • Developer 21st Century Therapeutics; Chengdu Xin Fanyu Biomedical; Sichuan New Phiaring Bio-medical Science
  • Class Chemoprotectants; Isoxazoles; Radioprotectives; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chemotherapy-induced damage; Radiation injuries; Sepsis

Most Recent Events

  • 15 Sep 2016 Chemical structure information added
  • 30 Jun 2014 Preclinical trials in Sepsis in China (unspecified route)
  • 30 Jun 2014 Preclinical trials in Sepsis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top